When considering the administration of live vaccines in relation to the use of Cosentyx (secukinumab), it is recommended to follow specific wait times to ensure the vaccine's efficacy and safety. Cosentyx is a human monoclonal antibody used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

According to the Cosentyx prescribing information, "the use of live vaccines should be avoided in patients treated with Cosentyx" [2]. However, if a patient has already received a live vaccine, it is suggested to wait at least two weeks before initiating Cosentyx therapy [2]. This recommendation is based on the general understanding that biologic therapies like Cosentyx may affect the immune system's response to vaccines [3].

It is essential to consult with a healthcare professional for personalized advice on vaccination schedules and potential interactions with Cosentyx. Healthcare providers will consider factors such as the patient's medical history, current health status, and the specific vaccine being administered when determining the ideal wait time [2].

In summary, the ideal wait time between receiving live vaccines and starting Cosentyx therapy is at least two weeks. However, it is crucial to consult a healthcare professional for personalized advice on vaccination schedules and potential interactions with Cosentyx.

Sources:
[1] Novartis Pharmaceuticals Corporation. (2021). Cosentyx (secukinumab) [Prescribing Information]. Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>
[2] DrugPatentWatch. (n.d.). Cosentyx (secukinumab) Drug Profile. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>
[3] Centers for Disease Control and Prevention. (2019). General Best Practices for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Retrieved from <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>